Results 91 to 100 of about 27,788 (185)

Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results. [PDF]

Oncologist
Spanggaard I, Matrana M, Rocha Lima C, Mahipal A, Vieito M, Hervieu A, Goyal L, Rodón J, Veronese ML, Oliveira N, Li X, Schaffer M, Kesari S.   +12 more
europepmc   +1 more source

Trifluoromethylation of Disubstituted Morpholines by Metal-Free Visible Light Photoredox Catalysis

, 2016
V. Srivastava, P. Singh, Praveen P. Singh   +2 more
semanticscholar   +1 more source

Optimizing Antiemetic Strategies Across Phases of Chemotherapy-Induced Nausea and Vomiting: Real-World Evidence in Breast Cancer. [PDF]

Curr Oncol
Doğan A, Erölmez HN, Akdağ G, Yıldırım S, Sever ÖN.   +4 more
europepmc   +1 more source

SnAP reagents for the synthesis of piperazines and morpholines.

Organic Letters, 2014
Michael U Luescher, C. Vo, J. Bode
semanticscholar   +1 more source

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report. [PDF]

Curr Oncol
Demers D, Florescu M.
europepmc   +1 more source

Efficacy and safety of tangweian recipe in the treatment of diabetic gastroparesis: a protocol for a non-inferiority, double-blind, active drug, randomized controlled clinical trial. [PDF]

BMC Complement Med Ther
Zhang YX, Yin RY, Zhang YJ, Ji HY, Ma JZ, Zhang C, Zhang LL, Wu XA, Li M, Tian JX.   +9 more
europepmc   +1 more source

Deoxygenative C(<i>sp</i>³)-N(<i>sp</i>³) Cross-Coupling Enabled by Nickel Metallaphotoredox Catalysis. [PDF]

J Am Chem Soc
Chen R, Kim T, Bissonnette NB, Martin RT, Martinelli JR, Cabré A, MacMillan DWC.   +6 more
europepmc   +1 more source

Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients. [PDF]

Acta Oncol
Väliaho VT, Spanggaard I.
europepmc   +1 more source

Stereoselective synthesis of morpholines via copper-promoted oxyamination of alkenes.

Organic Letters, 2012
F. C. Sequeira, S. Chemler
semanticscholar   +1 more source

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation. [PDF]

Oncologist
Kleinhenz F, Pfarr N, Steinhelfer L, Lörsch AM, Bendz H, Friedrich M, Liesenfeld L, Barroux M, Maurer C, Wenzel P, Kestler A, Koppermann ML, Mogler C, Spahn S, Illert AL, Schmid RM, Bitzer M, Lange S.   +17 more
europepmc   +1 more source